<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03896594</url>
  </required_header>
  <id_info>
    <org_study_id>HL237-102</org_study_id>
    <nct_id>NCT03896594</nct_id>
  </id_info>
  <brief_title>A Multiple Dose of HL237 in Healthy Male Subject</brief_title>
  <official_title>A Dose Block-randomized, Double-blind, Placebo Controlled, Dose-escalation Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics After Multiple Oral Dose of HL237 in Healthy Male Subject</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanlim Pharm. Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanlim Pharm. Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      HL237 is a new autoimmune therapeutic agent for rheumatoid arthritis, including the basic&#xD;
      structure of biguanide in metformin, an existing diabetes drug.&#xD;
&#xD;
      The immune modulating activity of HL237 was demonstrated in animal model. HL237 is a STAT3&#xD;
      inhibitor and STAT3 is well known for an important regulator inhibiting Th17 cells and&#xD;
      activating Treg cells.&#xD;
&#xD;
      Therefore, when STAT3 activity is inhibited, it is expected to be able to treat autoimmune&#xD;
      diseases such as rheumatoid arthritis.&#xD;
&#xD;
      This is the first repeated administration clinical trial performed for the development of&#xD;
      HL237 and is intended to evaluate the safety, tolerability and pharmacokinetics of each dose&#xD;
      group.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Doses are increased sequentially from low-capacity groups, and within six weeks after the&#xD;
      last dose of the last subject in the ongoing dose phase, if available pharmacokinetic data&#xD;
      are judged acceptable under review by investigators, sponsor and safety review committees,&#xD;
      then proceed to the next dose stage.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">December 24, 2018</start_date>
  <completion_date type="Anticipated">September 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Plasma Concentration [Cmax]</measure>
    <time_frame>14days after administration</time_frame>
    <description>maximum serum concentration after the drug has been administrated</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve [AUC]</measure>
    <time_frame>14days after administration</time_frame>
    <description>AUC after the drug has been administrated</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Half life [t1/2]</measure>
    <time_frame>14days after administration</time_frame>
    <description>Half life after the drug has been administrated</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events</measure>
    <time_frame>14days after administration</time_frame>
    <description>Adverse Adverse Events, Serious Adverse Events</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>HL237 200mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HL237 100mg 1 tablet twice a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HL237 400mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HL237 100mg 2 tablets twice a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HL237 800mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HL237 400mg 1 tablet twice a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HL237</intervention_name>
    <description>Experimental</description>
    <arm_group_label>HL237 200mg</arm_group_label>
    <arm_group_label>HL237 400mg</arm_group_label>
    <arm_group_label>HL237 800mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>placebo with same properties except for active ingredient</description>
    <arm_group_label>HL237 200mg</arm_group_label>
    <arm_group_label>HL237 400mg</arm_group_label>
    <arm_group_label>HL237 800mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  A healthy adult male aged 20 years or older and 45 years old at the time of the&#xD;
             screening test&#xD;
&#xD;
          -  Those who weigh more than 55kg but weigh less than Â± 20% of ideal body weight&#xD;
&#xD;
          -  Proper contraception during the clinical trial period&#xD;
&#xD;
          -  After hearing the detailed explanation of the clinical trial, those who decide to&#xD;
             participate voluntarily and write agreement&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinically significant, a person with a history of neurological, psychiatric,&#xD;
             malignant, cardiovascular, respiratory, kidney, endocrine, hematologic, digestive or&#xD;
             central disease&#xD;
&#xD;
          -  a person with a history of gastrointestinal disorders that may affect the absorption&#xD;
             of pharmaceuticals for clinical trials (Crohn's disease, ulcers, etc.) or&#xD;
             gastrointestinal surgery (except for simple cecal surgery or hernia surgery)&#xD;
&#xD;
          -  a person with a history of hypersensitivity or clinically significant hypersensitivity&#xD;
             to the clinical trial drug or additives&#xD;
&#xD;
          -  a person judged to be inappropriate for the subject by health screening (history of&#xD;
             disease, physical examination, vital signs, electrocardiogram, laboratory test, etc.)&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Seunghun Han</last_name>
    <phone>82-2-2258-7326</phone>
    <email>waystolove@catholic.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Catholic University of Korea, Seoul ST. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Seocho-gu</state>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seunghun Han</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 28, 2019</study_first_submitted>
  <study_first_submitted_qc>March 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2019</study_first_posted>
  <last_update_submitted>March 31, 2019</last_update_submitted>
  <last_update_submitted_qc>March 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

